Journal issues > Issue 7, November 2021 > Belgian guidelines on supportive care: Cardiotoxicity of cancer treatments

Belgian guidelines on supportive care: Cardiotoxicity of cancer treatments

By: B. von Kemp MD, On behalf of the BSMO Supportive Care Taskforce

SUMMARY

Increasing effectiveness of cancer treatments significantly improved patient survival. More treatment options are available for frailer patients. Therefore, the importance of appropriate supportive care measures increases, particularly in high-risk patients. More data concerning potentially cardiotoxic effects of cancer therapies are available, involving multiple cardiovascular side-effects. We provide an overview of available strategies to identify the patient at increased risk for cardiotoxicity, to prevent, detect and treat cardiotoxic effects of cancer treatments and to organise follow-up in patients with documented toxicity. The main focus will be left ventricular dysfunction and heart failure, but some other frequently encountered forms of toxicity will be discussed.

(BELG J MED ONCOL 2021;15(7):367-73)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top